earnings
confidence high
sentiment neutral
materiality 0.75
AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M
AtriCure, Inc.
2021-FY EPS reported
$1.09
revenue$274,329,000
- Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).
- FY2021 revenue $274.3M (+32.8%); GAAP net income $1.11/shr; adj loss per share $1.16.
- FY2021 includes $184.8M credit for contingent consideration change and $82.3M IPR&D impairment.
- FY2022 revenue guidance $315-330M (15-20% growth); adj EBITDA loss $2-4M; adj loss/shr $1.07-1.12.
- Milestones: Hybrid Therapy FDA approval, ENCOMPASS 510(k), Cryo Nerve Block expansion.